Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Sun Pharma has had another setback in its manufacturing for the U.S. market with the FDA laying out nearly a dozen observations for a solid dose formulation…
Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…
Fujifilm is investing about $130 million in its U.S. and U.K. plants to increase biologics manufacturing as it races to capture a piece of the growing business.
The FDA has nailed another Teva manufacturing facility with a warning letter, this time for an API facility in China.
Another Mylan plant in India has been issued a warning letter.
Samsung Biologics is on track to complete its third manufacturing plant in Songdo, Incheon, this year.
The FDA has nailed India's Indoco with a warning letter for a sterile and solid dose plant in Goa because of its concerns over an injected drug.
For the second time in six weeks, Dr. Reddy’s has been rebuffed by the FDA for its efforts to deal with problems outlined in a warning letter two years ago.
After a year of nothing but bad news about FDA citations of its plants, India’s Alkem Laboratories has announced something positive.